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Abstract
Objective: The aim of the study to evaluate the effectiveness of oral and injection intra-
tympanic methylprednisolone to treat acute tinnitus associated with idiopathic sudden 
sensorineural hearing loss.
Study design: Analytical, prospective and longitudinal study.
Setting: Brasilia Institute of Otorhinolaryngology.
Subjects and methods: Twenty‐three subjects with acute tinnitus and idiopathic sudden 
sensorineural hearing loss, 13 treated with oral steroids only (Group 1) and 10 treated 
with methylprednisolone intratympanic injection as rescue therapy (Group 2), and evalu-
ated by audiometry, otoacoustic emission, tinnitus handicap inventory (THI) and visual 
analog scale (VAS) to assess the degree of tinnitus annoyance, before treatment and after 
3 months.
Results: The annoyance due to tinnitus resulted in a mean VAS of 7.69 in the beginning of 
treatment and 5.15 3 months after treatment (Group 1), and 8.30 at the beginning and 6.00 
3 months later (Group 2). In THI, average was 64.77 points at the beginning of treatment 
and 49.92 points 3 months later (Group 1) and 72.20 points at the beginning and 51.60 
points after 3 months (Group 2). The results of audiometry and otoacoustic emissions 
showed significant improvement in both groups with significant differences intragroups 
before and after, but not between the groups.
Conclusion: The results suggest that both oral and injection intratympanic methylpred-
nisolone are effective treatment for acute tinnitus associated with idiopathic sudden 
sensorineural hearing loss in these patients.
Keywords: tinnitus, idiopathic sudden sensorineural hearing loss, treatment, 
intratympanic, corticosteroids
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1. Introduction
Tinnitus is a complex disorder and is presented as a hearing sensation, which is not associated 
with an external sound stimulus [1]. It probably arises initially in the cochlea and later reaches 
higher structures of the auditory system where it becomes sometimes very annoying (severe 
disabling tinnitus—SDT).
One study showed 10 patients with “predominantly cochlear tinnitus” treated using intra-
tympanic dexamethasone injections and described 5 patients with tinnitus control for at least 
1 year [2]. They did not use a control group.
The effectiveness of intratympanic dexamethasone injections as a treatment for SDT was stud-
ied [3]. A control group was treated with saline solution and a study group with dexametha-
sone solution, both using intratympanic injections. There was no statistic significant difference 
between saline and dexamethasone solution regarding tinnitus improvement measured with 
visual analog scale (VAS). They concluded that intratympanic injections of steroids are not 
effective for the treatment of chronic SDT.
For acute tinnitus, interventions such as intratympanic AM‐101 (a cochlear N‐methyl‐D‐aspartate 
receptor antagonist) were tested. However, there is insufficient evidence to support the safety 
and efficacy of this intervention [4]. A second phase study was carried out, randomized, and 
placebo controlled using AM‐101 intratympanic injections and concluded that the duration of 
symptoms affected the cure rate of intratympanic therapy for acute subjective tinnitus [5].
The management of subjective tinnitus associated with idiopathic sudden sensorineural hear-
ing loss (ISSHL) includes oral, intravenous, and/or intratympanic administration of cortico-
steroids as initial therapy [6]. Intratympanic corticosteroids were effective for the treatment 
of idiopathic sudden sensorineural hearing loss (ISSHL) in controlled trials when used as 
primary therapy [7] or as rescue therapy after failure of initial oral steroids therapy [6].
The sudden sensorineural hearing loss (SSHL) is a hearing loss of at least 30 dB at three con-
secutive frequencies occurring in the period of 3 days or less [8] may occur in frequencies and 
intensities varying from a mild hearing loss to a total loss of hearing [9, 10].
SSHL is often accompanied by tinnitus and there are few theories trying to explain its mecha-
nism. One of them associates this symptom to a maladaptive attempt at cortical reorganiza-
tion process due to peripheral deafferentation [7].
Many of these patients with tinnitus and SHL remain with residual buzz even if the treatment 
for SHL has been effective. The treatment of sudden sensorineural hearing loss is based on its 
etiology. In idiopathic sudden sensorineural hearing loss (ISSHL), the oral corticosteroids are 
widely used, although the supporting evidence is weak. Injection intratympanic dexametha-
sone has been tried in patients with idiopathic sudden sensorineural hearing loss because it 
provides a high concentration of steroids in the labyrinth in animal models [8]. In addition, 
there are several advantages to intratympanic treatment. The procedure is well tolerated, rela-
tively easy to perform as outpatient. Most patients understand the concept of intratympanic 
treatment and easily accept this therapy [3].
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The questions we try to ask in this paper are as follows:
1. Are steroids intratympanic injections effective in the treatment of acute tinnitus? (As in 
ISSHL).
2. If so, what explains the fact it is not effective to treat chronic SDT?
2. Methods
The study protocol and procedures were approved by the Research Ethics Committee (REC) 
University of Brasilia (Opinion number 132/2012). All patients received information about the 
risks and expectations of therapy and signed a free informed consent form (FICF) accepting 
their participation in the study.
This is an analytical, prospective and longitudinal study, and the data were analyzed between 
January (2014) and June (2015).
Patients with middle ear diseases; presence of air type tympanogram, Ad, Ar, B, or C; prior 
ear surgery; signs of acute or chronic otitis media; history of Meniere’s syndrome or fluctuat-
ing hearing; and history of prior sensorineural hearing loss were excluded (Figure 1).
From the initial sample of 38 patients with acute tinnitus and idiopathic sudden hearing 
loss, 23 were enrolled, 13 in the oral steroid therapy group (Group 1/oral therapy) and 10 
in the intratympanic corticosteroids group after failure of oral therapy (Group 2/rescue 
therapy).
Tinnitus handicap inventory (THI) [11] and visual analog scale (VAS) were used for evalu-
ation of tinnitus annoyance. For audiological assessment, tonal and vocal audiometry were 
used. (Diagnostic audiometer Madson Itera II) and for distortion products otoacoustic emis-
sion (DPOAE) measurements OtoRead Portable Interacoustic device was used.
A detailed clinical history was taken, followed by an otoneurological examination and audio-
logical assessment by tonal and vocal audiometry. DPOAE measurements and application of 
THI [11] and VAS were carried out before onset of therapy and 3 months later [6].
All patients underwent pure‐tone audiometry (PTA) and speech audiometry carried out by 
the same audiologist before and after treatment. The mean was calculated based on pure‐tone 
average at 500, 1000, 2000, and 4000 Hz [12].
For DPOAEs, primary tones f1 and f2 were presented at 55 and 65 dBSPL (sound pressure 
levels). The f2/f1 ratio was kept at approximately 1.2. The levels of the DPOAE at 2fi–f2 were 
recorded in four different frequencies (ranging between 2000 and 5000 Hz), DP‐gram showed 
DP1 level (dB) and DP1 signal‐to‐noise ratio (dB).
All patients were treated with systemic oral therapy according to the local protocol (1 mg/kg/
day prednisolone for 10 days, followed by decreasing doses thereafter). Next, rescue therapy 
with intratympanic methylprednisolone was offered after systemic therapy failed and no 
improvements were demonstrated audiometrically in 10 patients (Group 2).
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Initially, EMLA cream was applied (AstraZeneca, Wilmington DE) for topical anesthesia in 
the external auditory canal and the tympanic membrane and left for 30–45 minutes. Then, 
the patient’s head was placed at 45° in the direction of the affected ear. A solution of 40 mg of 
methylprednisolone/ml was warmed to body temperature. About 0.3–0.5 ml of the solution 
was injected into the middle ear; two holes were made with the application of needle (Gelco 
N.22), one just below the umbo (where the drug was administered) and another in the upper 
Figure 1. Schematic diagram.
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posterior region (vent). After intratympanic application of the steroid, the patient remained in 
the injection position with head turned 45° for 30 minutes to maximize exposure of the round 
window membrane to the solution and were applied three injections every 48 hours.
The criteria for defining successful recovery after therapy vary in the literature on intratym-
panic therapy. The hearing recovery was analyzed in three categories: (A) complete recovery 
when there was improvement ≥ 30 dBHL (hearing loss) in the affected frequencies; (B) partial 
recovery, when there was improvement ≥ 10 dBHL and ≤ 30 dBHL in the affected frequencies; 
(C) no recovery when there is an improvement of ≤ 9 dBHL [13]. Failure of oral prednisolone 
therapy was absence of improvement, as just described, after 14 days of treatment [14].
All patients answered the THI [11] and the VAS to assess quantitatively and qualitatively 
the therapeutic response in relation to tinnitus. In the VAS, score ranges from 1 to 10, where 
10 represents the highest degree of tinnitus severity. Scores measured the intensity and dis-
comfort of tinnitus. Two points in the VAS were considered significant change [3]. The THI 
questionnaire was considered improved when there was change of category of tinnitus sever-
ity in the following scale: Grade 1 negligible (0–16), Grade 2 light (18–36), Grade 3 moderate 
(38–56), Grade 4 severe (58–76), and Grade 5 catastrophic (78–100) [11].
The average posttreatment for some measures were compared between types of treatment 
(oral therapy and intratympanic corticosteroids after failure of oral therapy) using an analysis 
of covariance model (ANCOVA). In the ANCOVA model, the measurement obtained after 
treatment was considered the dependent variable, the type of treatment as the independent 
variable and the measures at baseline as the covariate. Mean comparisons were made with the 
intragroup test employing Student t‐test for paired samples. Note that p < 0.05 was considered 
significant. The analysis was performed using SAS v 9.4 (SAS Institute, Inc., 2012).
3. Results
There were 23 subjects in the total, 13 subjects (6 female and 7 male, mean age = 38.30 years) 
in the oral steroid therapy (Group 1) and 10 subjects (7 female and 3 male, mean age = 47.40 
years) in the intratympanic corticosteroids after failure of oral therapy (Group 2).
The average total score in THI before in Group 1 (n = 13) was 64.77 points, and after oral therapy, 
it was 45.90 points. The mean of the THI score before intratympanic corticosteroids after failure 
of oral therapy (Group 2) (n = 10) was 72.20 points and 47.73 points after (Figure 2). The mean 
VAS value in Group 1 was 7.69 points before and 5.30 points after therapy. The average value 
in VAS for the Group 2 was 8.30 points before and 5.81 points after therapy (Figure 3). THI and 
VAS averages showed a significant decrease when comparing the values before and after treat-
ment intragroups (p < 0.05), whereas the analysis between groups was not statistically different.
In pure tone audiometry, we found the average of 74.23 dB (Group 1) before and 59.69 dB 
after therapy and 86.50 dB before and 51.91 dB after therapy (Group 2; Figure 4). A significant 
decrease in pure tone thresholds was found when comparing the values before and after treat-
ment intragroups (p < 0.05), whereas the analysis between groups was not statistically different.
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Figure 4. PTA results before and after treatment.
Figure 2. THI results before and after treatment.
Figure 3. VAS results before and after treatment.
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In the DPOAE test, we found in Group 1 the following amplitude values before and after therapy: 
for frequencies of 2 KHz: −10.08 and −1.69 dB; 3 KHz: −9.77 and −1.85 dB; 4 KHz: −10.92 and 
−5.08 dB; and 5 KHz: −10.69 and −2.85 dB. As for Group 2, the following amplitude values were 
obtained before and after treatment, respectively: 2 KHz: −12.30 and −3.90 dB; 3 KHz: −12.00 and 
−7.10 dB; 4 KHz: −11.30 and −6.10 dB, and 5 KHz: −12.60 and −4.40 dB (Figure 5).
As for the S/N ratio, the following values were obtained in Group 1 before and after therapy, for 
each frequency tested: 2 KHz: 2.77 and 8.38 dB; 3 KHz: 2.23 and 8.69; 4 KHz: 0.00 and 7.85 dB, 
and 5 KHz: 1.23 and 8.08 dB (Figure 6). We found a significant decrease when comparing the 
amplitude values before and after treatment intragroups (p < 0.05) in the four analyzed frequen-
cies (2, 3, 4, and 5 KHz), while the analysis between groups did not show statistical difference.
The S/N ratios were as follows before and after treatment, respectively: 2 KHz: 0.00 and 7.10 
dB; 3 KHz: 0.50 and 7.10 dB; 4 KHz: 1.00 and 4.30 dB, and 5 KHz: −0.70 and 4.50 dB (Figure 6). 
There was decrease when comparing signal/noise values before and after treatment intra-
groups (p < 0.05) in four analyzed frequencies (2 and 5 KHz), while the analysis between 
groups was not statistically different.
Figure 5. Amplitude results before and after treatment.
Figure 6. Signal/noise results before and after treatment.
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4. Discussion
In this study, the treatment of sudden deafness and acute tinnitus with intratympanic cortico-
steroids after failure of oral therapy (rescue) was effective. The findings were consistent with 
the study in which the THI and VAS scores were significantly reduced after intratympanic 
steroids injections, and it was concluded that these scores were useful for assessing tinnitus 
patients, as well as it [15].
The intratympanic therapy is currently in use for ISSHL, Meniere’s disease, tinnitus associ-
ated with these disorders and idiopathic tinnitus [15]. In previous studies, positive results 
of intratympanic steroids injections were reported for chronic subjective tinnitus [2, 16, 17], 
but they did not use the control group. Statistic significant difference between saline and 
dexamethasone solution when a control group was used regarding tinnitus improvement 
measured with visual analog scale (VAS).
A systematic review was conducted to determine the efficacy of intratympanic steroids treat-
ment. It emphasized that this treatment should be considered as an adjuvant one in sudden 
deafness [18] consistent with the findings of this study.
The analysis of the characteristics of sudden deafness in 105 patients pointed out that there 
are individual differences in clinical characteristics between patients with tinnitus and ISSHL 
hindering a single treatment line [19]. We emphasize that both groups of this study were 
homogeneous, showing no statistical difference in age, sex, and affected ear.
By examining variables such as gender, age, and laterality in relation to changes in the level 
of tinnitus after the start of ISSHL, our results corroborate previous studies in which patients 
requiring rescue therapy were those in which oral therapy had not been sufficient to improve 
the hearing thresholds. Some patients improved hearing thresholds but remained with resid-
ual tinnitus [20].
Overall good results were reported in 77% of patients with tinnitus and various diseases 
immediately after the intratympanic dexamethasone treatment [21] and found that the best 
results of intratympanic therapy for tinnitus are obtained in patients with a shorter duration 
of tinnitus, especially when treatment was initiated within 3 months of symptom onset [17]. 
The effectiveness of intratympanic injection of prednisolone or dexamethasone to treat subjec-
tive tinnitus was reported to be 48.6 and 37.5%, respectively [22].
Similar results were found by other researchers that recommended intratympanic therapy as a 
possible option in the treatment of tinnitus to a certain group of patients [3, 23]. No difference 
in results was observed in patients between 3 and 6 months after treatment [23].
The shorter the period from onset of sudden deafness to the start of intratympanic treatment 
with dexamethasone, the greater the improvement in tinnitus that could be expected after 
treatment [24]. There is no significant difference after 3 months [6].
In this study, we chose to use intratympanic corticosteroid as rescue after failure of oral corti-
costeroids. We found that this association was particularly effective in relation to tinnitus. In 
Group 2, VAS and THI showed a significant reduction of tinnitus annoyance after intratympanic 
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steroids therapy. Probably, these results are due to the fact that the rescue treatment was initi-
ated immediately after the oral treatment did not show the desired results.
It is significant the correlation between the degree of hearing recovery and subjective improve-
ment of tinnitus after treatment. It was suggested that the hearing improvement may be a 
prognostic factor for tinnitus improvement, but the presence of tinnitus was not a prognostic 
factor for the recovery of hearing [25]. These findings are similar to those of the present study.
In this study, Group 2 had increase in the amplitude of DPOAE in all frequencies. There are 
studies in the literature that demonstrate a prognostic role for OAEs in the ISSHL [21, 26]. 
Other studies do not agree with this [27, 28].
The DPOAE is detectable in three of five patients whose hearing had significantly improved. 
It is suggested that the presence of DPOAE can be a useful prognostic factor that positively 
correlates with the recovery of the SHL [29].
It is reported a significant increase in the amplitude of DPOAE among patients who regained 
their hearing and also found significant correlations between improvement in DPOAE and 
improved hearing. It was stated that the presence of DPOAE predicted improvement in hear-
ing [28, 30]. Our study is in agreement with these previous studies.
The detection of OAE during the first 15 days after starting treatment, even with no improve-
ment in hearing, would suggest the high sensitivity of this test to detect improvement changes 
in the activity of outer hair cells [31].
The sudden deafness factors that predict a favorable prognosis are still controversial. Clinical 
recovery was estimated by the difference between the audiometric results on admission and 
the audiometric results 10 days later. Only two factors were significantly associated with 
improved hearing: tinnitus (p < 0.04) and the configuration of ascending audiometric curve at 
admission (p < 0.045) [32]. In this study, most subjects had flat audiometric curve.
Tinnitus was cured in 43 of 114 patients (37.7%) within 3 months. In our study, THI was sig-
nificantly reduced after intratympanic dexamethasone, and this cure rate was significantly 
higher in patients with symptoms lasting 2 weeks or less. The authors concluded that the 
duration of symptoms affected the intratympanic dexamethasone cure rate for acute subjec-
tive tinnitus [33].
The feeling of ear fullness and tinnitus in ISSHL was compared in one study that found they 
were primarily associated with poorer hearing thresholds at high frequencies. They con-
cluded that tinnitus is probably originated in the region where the hair cells are damaged 
[34]. Steroid intratympanic therapy for acute tinnitus was found effective. SSHL patients were 
excluded from that study. Our study is about ISSNHL patients with tinnitus that is necessar-
ily acute.
Steroids were likewise effective for these patients. Probably, the short time from onset of tin-
nitus is the determinant factor to predict the effectiveness of steroids therapy.
Our study has some limitations that should be pointed out: we did not have a control group, 
as this group would be composed of patients who failed on oral therapy and were not treated 
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with rescue therapy, which would not be correct from the point of view ethics and the num-
ber of patients is small in preliminary studies. Therefore, to confirm our results, we should 
consider a larger number of patients in future studies.
5. Conclusions
Our results as well as other studies seem to point out to the effectiveness of steroids for the 
treatment of acute tinnitus. Both oral and intratympanic steroids were effective in our study. 
Intratympanic steroids improved tinnitus further in patients that did not respond well to oral 
steroids. The higher concentration of steroids in inner ear fluids after intratympanic injection 
probably explains this result.
Why steroids are effective to treat acute tinnitus and not to treat chronic tinnitus? We believe 
tinnitus start in the cochlea almost always. Later the cochlea lesion causes changes in cen-
tral pathways that in some patients make the symptom permanent and extremely annoy-
ing‐severe disabling tinnitus (SDT) [2]. If tinnitus is treated before it sets foot in the central 
pathways (acute tinnitus), steroid therapy is effective.
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